Key facts
- Medmain’s last known valuation is $21.1M (Feb 2026).
- It has raised $19.6M; the latest was Merger/Acquisition ($14.8M) in Feb 2026.
- Notable investors include Plug and Play Tech Center, J-Startup, Deepcore, One Capital (Tokyo), Fukuoka Growth Next — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Medmain
- ·The full record, as it builds
Funding rounds
No funding rounds for Medmain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medmain
Developer of a cloud-based platform designed to assist in digital pathology through AI-powered image analysis and remote diagnostics. The company's platform offers deep learning-driven pathological screening, telepathology capabilities, and secure cloud storage to conduct pathological image diagnosis, enabling medical institutions and professionals to enhance diagnostic accuracy and efficiency and improve patient care.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2017
- Employees
- 40
- Website
- medmain.com/
- Ownership
- Privately Held (backing)
Medmain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medmain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medmain in its N-PORT filings yet. We sweep new filings monthly.